Background: Glibenclamide (BCS Class–II .Drug) has poor solubility and high permeability. In the co-crystallization technique, drugs are combined with a suitable coformer via Hbonding. Glibenclamide cocrystals have been prepared with various coformers but glibenclamide cocrystals with vanillic acid have not been prepared yet. Objective: To prepare glibenclamide cocrystals with vanillic acid coformer and evaluate them using various techniques, along with in vivo antidiabetic studies and stability studies. Method: Cocrystals containing glibenclamide were produced with vanillic acid coformer by the solvent evaporation method in a 1:1 molar ratio. Result: In FTIR analysis, an H-bond is formed between the amide group of the drug and the carboxylic acid group of the coformer. With the help of DSC and HSM, the melting point of cocrystals was observed at a different point compared to the melting point of glibenclamide drug and vanillic acid coformer. In the XRD analysis of cocrystals, peaks with high intensity were observed at different points than that of the drug and coformer, confirming the crystalline nature of the formulation. During in vitro dissolution studies, cocrystals showed a better dissolution profile compared to the marketed formulation and the pure drug in both acidic and alkaline media. In vivo anti- diabetic studies were conducted using male Wistar rats, confirming that the glucose reduction percentage from cocrystals was more than that of the pure drug. During stability studies, no significant changes occurred in the dissolution profile of the formulation, which indicated that the formulation was stable after storage at an ambient temperature. Conclusion: The results obtained from various characterization techniques indicate that glibenclamide cocrystals formed from vanillic acid enhance the solubility of glibenclamide.

Background: Piroxicam (PRX), a nonsteroidal anti-inflammatory drug, exhibits poor aqueous solubility, limiting its therapeutic efficacy. Enhancing solubility can directly improve bioavailability and therapeutic effectiveness. This study explores the development of a new solid dispersion (SD) system of PRX using polyvinylpyrrolidone (PVP K30) as a carrier by MW-assisted method. Methods: The involvement of microwave (MW) in the solvent evaporation method is a newer concept aimed at enhancing the solubility and in vivo bioavailability of PRX. Various ratios of PRX: PVPK30 (1:5, 1:7, 1:9, and 1:11 w/w) were evaluated using conventional and MW-assisted solvent evaporation methods and conducted in vitro dissolution studies. Results: The optimized MW-assisted formulation (1:7 w/w) exhibited 94.69±0.24% drug release in 15 minutes, showing a 5.37-fold increase compared to pure PRX (17.63%) and surpassing the marketed drug release (90.82±0.39%). Fourier Transform Infrared, Differential Scanning Calorimetry, Thermogravimetric analysis, Scanning Electron Microscopy, and powdered X-ray diffraction authenticated the OF. In vivo studies demonstrated significant enhancements (p<0.0001) compared to control. The anti-inflammatory activity showed increased paw oedema inhibition (44.4±0.4%) compared to control and pure PRX (35.37±0.3%). The analgesic activity of OF demonstrated improved pain response time (10.6±0.8 seconds) compared to control (4.2±0.5 seconds) and pure PRX (8.1±0.7 seconds). Conclusion: The SD developed via the MW-assisted drug formulation technique significantly enhances the solubility, bioavailability, and therapeutic efficacy of PRX, offering a potential strategy to improve clinical outcomes for similar drugs with solubility challenges.

Objective: The present work aims to prepare and characterize glibenclamide cocrystals. Methods: Glibenclamide was chosen as a model drug due to its low solubility and classification as a Biopharmaceutical Classification System (BCS) class II drug. Among the various methods for selecting appropriate coformers, the pKa and thermal methods were employed. Using these approaches, a formulation with caffeic acid, prepared through the solvent evaporation method, demonstrated the best results as evaluated by parameters such as dissolution rate, X-ray diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Hot Stage Microscopy (HSM), Scanning Electron Microscopy (SEM). Results: In the FTIR spectra, the sulfonamide group of the drug formed hydrogen bonds with the hydroxyl groups of the coformer, suggesting the presence of hydrogen bonding interactions between the components. HSM and DSC revealed that the melting point of the cocrystals occurred at a different temperature for the pure drug and coformer. This significant change in the melting point indicates the formation of a new crystalline phase in the cocrystals, suggesting that the drug and coformer interact at the molecular level to form a unique solid structure. XRD analysis showed diffraction peaks at distinct points with higher intensity in the cocrystals, indicating a new crystalline structure. SEM images of the cocrystals revealed a well-defined crystalline morphology, which differed from the irregular shapes of the pure drug and coformer. The cocrystals demonstrated a significantly improved dissolution rate compared to the pure drug and marketed formulation. In animal studies conducted on male Wistar rats, cocrystals reduced blood glucose levels more rapidly than pure glibenclamide. This enhanced antidiabetic efficacy suggests that the cocrystal formulation not only improves dissolution but also accelerates the therapeutic onset of action. Conclusion: These findings confirmed that the glibenclamide cocrystals prepared with caffeic acid help effectively improve the drug’s low solubility.

Aims The aim of this research work was to investigate the potential ability of cilnidipine-loaded-Self-Emulsifying Drug Delivery System (SEDDS) to improve the solubility and oral bioavailability of cilnidipine.Background The therapeutic value of drugs is constrained by the low oral bioavailability of BCS class II drugs. In order to improve the solubility and oral bioavailability of poorly water-soluble drugs, SEDDS are frequently utilised.Methods To develop the cilnidipine-loaded-SEDDS formulation, Canola oil as the oil phase, tween 80 as the surfactant, and PEG 300 as the co-surfactant were used. The SEDDS formulation was evaluated based on stability study per ICH guidelines, drug precipitation during in-vitro lipolysis study under fasted and fed state, and in vivo pharmacodynamic study in Wistar rats. The content of the drug was determined by assay of SEDDS formulation using the official method of cilnidipine.Results The pharmacodynamic study demonstrated that cilnidipine-loaded SEDDS formulation significantly produced a rapid antihypertensive effect (within 2 h) that lasted for 24 h in comparison to drug suspension. During the in vitro lipolysis study, the concentration of the drug recovered from the aqueous phase under both fasted and fed state was more than 90% after 10 minutes, with a minute amount of drug involved in precipitation. At stability conditions of 30 +/- 2 degrees C/65 +/- 5%RH for a duration of six months, the SEDDS formulation was found to be stable. The content of cilnidipine in the SEDDS formulation was found to be 98.4%.Conclusion A BCS class-II drug's oral bioavailability and dissolution might be improved using the self-emulsifying drug delivery method.

The article has been withdrawn at the request of the authors of the journal Pharmaceutical Nanotechnology. Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/pages/editorial-policies-main Bentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

Background: In the present investigation, nano-lipid technology was exploited to control the release of celecoxib (CXB) and overcome its dissolution problem. Solid lipid nanoparticles (SLNs) have a small particle size (50-1000 nm) that results in a large surface area-to-volume ratio, which further enhances the contact between the drug and the dissolution medium. This leads to improved drug release and absorption. Aim and Objective: This study aimed to enhance the solubility and hence improve the therapeutic efficacy of a BCS Class-II drug-celecoxib formulating it as solid lipid nanoparticles. Methods: CXB-loaded-SLNs were prepared using the solvent emulsification-diffusion technique and optimized by CCD. Characterization included FTIR, drug loading, particle size, PDI, zeta potential, and in-vitro release and anti-inflammatory studies. Results: Optimized Formulation (OF1) exhibited particle size, PDI, and zeta potential were found to be 314 nm, 0.204, and -18.73 mV, respectively, with entrapment efficiency (79±0.18 %) and drug loading (44.38±0.21 %). The best-fitted model was the Korsemeyer-Peppas model, with drug release of 89.42 ±0.12 % in 24 h. OF1 formulation reduced the rat paw volume to a minimum (1±0.32) in 24 h when compared to pure API (2±0.62) and marketed preparation (2±0.42). Conclusion: OF1 demonstrated sustained drug release with enhanced solubility and better in-vivo anti-inflammatory studies compared to pure API.

Hyperlipidemia is a worsening health condition in developed and developing countries, especially among the younger generation due to their lifestyle. The World Health Organization reported 2.6 million deaths globally due to hyperlipidemia. Therefore, there is a huge demand of antihyperlipidemic drugs in the pharmaceutical market. Approximately 60% of the total active drug content used in hyperlipidemia suffer from poor water solubility, particularly BCS class II drugs. Poor water solubility may result in insufficient absorption and finally affects the bioavailability of the drug causes ineffectiveness in lowering lipid profile of patients. In recent years, solid dispersion technology has proved to be a simple, effective and economical approach for industrial application to increase the solubility of these drugs. This review paper is an attempt to compile up various research as well as patents reports related to solid dispersions of poor water soluble antihyperlipidemic drugs.

Purpose The primary objective of this research work was to formulate crystal engineered multicomponent form of a BCS II drug, telmisartan (TEL) using crystal engineering approach to improve its aqueous solubility. Further, it was attempted to understand the co-crystallization specificity of TEL using a set of structurally similar coformers. Methods Preliminary structural assessment and feasibility of cocrystal formation was done using Cambridge structural database (CSD) and molecular electrostatic surface potential (MESP). The formation of cocrystals was confirmed by different characterization techniques such as differential scanning calorimetry (DSC), hot stage microscopy (HSM), Fourier transform infrared spectroscopy (FTIR), and powder x-ray diffraction (PXRD). Solubility and dissolution studies were performed in phosphate buffer 7.5 and 0.1 N HCl. Results TEL cocrystal with maleic acid (MA) was successfully obtained, and co-crystallization specificity was decoded at MESP. Cocrystal structure was also solved from PXRD data. A 4.27-fold and 2.8-fold improvement in the solubility was observed in phosphate buffer 7.5 and 0.1 N HCl. Conclusion A significant improvement in the aqueous solubility and dissolution profile was observed for the prepared cocrystals over the pure TEL. The present study was a small initiative to serve as a guidance for the rationalized screening and preparation of novel multicomponent solids with desired properties.

Various drugs are not able to reach the market due to their poor bioavailability and poor solubility in aqueous media. Hence, several approaches are used to enhance the solubility of poorly water-soluble drugs. Co-crystallization is one of the approaches used to enhance the solubility of poorly water-soluble drugs. Co-crystals are solid crystalline substances consisting of two or more ingredients in a stoichiometric ratio in which one of the ingredients is an active pharmaceutical ingredient (API) and the other is a co-former. API and co-former mix with one another in a co-crystal through intermolecular interactions. This review represents an overview of co-crystals, a comparison of co-crystals and other solid forms, mechanisms of solubility enhancement by co-crystals in brief, techniques of co-former selection, a list of co-formers used during various co-crystals formation and a list of marketed co-crystals formulation, method of co-crystals preparation and characterization techniques of co-crystals.

Background: SIM is a poorly water-soluble drug with dissolution-dependent bioavaila-bility. A solid dispersion and self-emulsifying drug delivery system was developed, optimized, and evaluated to improve its bioavailability. The permeability coefficient in rats was determined using the in-situ single-pass intestinal perfusion (SPIP) technique. Further, the permeability coefficient (Peff, humans) was used to calculate the permeability and fraction of SIM bioavailable to humans which have not yet been reported for these formulations. Objective: To estimate and compare various formulations of Simvastatin (SIM) for bioavailable fraction to humans (Fa) as a function of solubility enhancement. Methods: In this study, the preparation and evaluation of SIM formulations i.e., Self-emulsifying drug delivery system (SEDDS) and Solid dispersions (SD) are discussed in brief. An uncomplicat-ed, precise, and accurate HPLC method was validated for simultaneous determination of SIM and phenol red as per ICH guidelines. A comparative in-vitro dissolution test, pharmacokinetic studies, and in-situ SPIP technique in rats were carried out amongst optimized formulations of SIM-SD and SIM-SEDDS, SIM suspension (SIM-SUSP), and SIM marketed preparation (SIM-MP). Results: The HPLC method was successfully validated. In-vitro dissolution test displays that both the SIM formulations i.e., SIM-SEDDS and SIM-SD shows better dissolution rate than SIM-MP and SIM-SUSP. Pharmacokinetic studies revealed that SIM-SEDDS, SIM-SD, and SIM-MP showed significant differences when compared to SIM-SUSP in terms of Cmax, [AUC] 0-∞, at P ≤ 0.05. The comparison of permeability coefficient between SIM SEDDS vs. SIM MP and SIM SEDDS vs. SIM SD were non-significant. In contrast, SIM- SUSP vs. all other formulations were significantly different at P ≤ 0.05 (employing two-way ANOVA followed by post-Bonferroni Test). Fa for SIM SUSP, an optimized formulation of SIM-SEDDS, SIM-MP, and SIM-SD are 0.353, 0.977, 0.975, and 0.987 respectively. It is revealed that SIM-SEDDS and SIM-SD showed enhanced absorption and the results are confirmed by in-vitro data, pharmacokinetic studies, and In-situ SPIP techniques. Conclusion: The permeability prediction method is a rapid and economical method for screening chemical compounds with the least possible utilization of resources. So, its use can be extended in prime and initial screening prototypes for the evaluation of compounds in the early stages of their formulations.

Preventing the development of cardiovascular problems is a key objective of antihypertensive drugs. Many of the non-pressure related coronary risk factors for hypertension are thought to be connected to an increase in sympathetic activity. The sympathetic systems have N-type calcium channels at the nerve terminals that control neurotransmitter release. Cilnidipine is a unique fourth-generation calcium channel blocker with blocking action on both L-/N- type calcium channels. Several L-type calcium channel blockers (Nilvadipine, amlodipine, azelnidipine, nifedipine, etc.) have been used to treat hypertensive patients. Cilnidipine is a novel drug that exerts a hypotensive effect through vasodilation action via blocking L-type calcium channels and potent antisympathetic activity via blocking N-type calcium channels. Inhibiting N-type calcium channels might be a new approach to treating cardiovascular disorders. Therefore, it is expected that cilnidipine may respond well to complicated hypertension. The present review aims to describe the management mechanism of hypertension, and other pharmacological and physicochemical properties of cilnidipine. Cilnidipine has various other beneficial effects such as lipid-lowering effect, reduced white coat effect, improves insulin sensitivity in essential hypertensive patients, ameliorates osteoporosis in ovariectomized hypertensive rats, reduced arterial stiffness, reduced the risk of pedal edema, antinociceptive effects, neuroprotective and renal protective effect, probably through inhibition of N-type calcium channels. Cilnidipine distinguishes itself from other calcium channel blockers due to its wide range of beneficial pharmacological effects. In conclusion, cilnidipine may be more advantageous than other dihydropyridines, such as nisoldipine, amlodipine, azelnidipine, and other antihypertensive drugs.

Aim: The goal of this research was to formulate and optimize a cost-effective self-emulsifying drug delivery system (SEDDS) of cilnidipine to increase its dissolution rate. Cilni-dipine is a BCS class II active pharmaceutical ingredient, which limits its use. Methods: Cilnidipine's solubility in various oils, surfactants, and cosurfactants, has been investigat-ed. To determine if there is any interaction between cilnidipine and certain excipients, drug compat-ibility tests were carried out. Based on phase solubility and compatibility studies, two combinations (Canola oil, Tween 80, and PEG 300; Peanut oil, Cremophor EL, and PEG 200) were prepared to create ternary phase diagrams for selecting the best combination with higher microemulsion region and to identify the range of concentration of excipients. Cilnidipine-loaded-SEDDS formulation was prepared by incorporating Canola oil, Tween 80, and PEG 300. For achieving the best formula-tion, D-optimal mixture design was used. The optimized SEDDS formulation was evaluated for globule size, zeta potential, drug release, drug content, self-emulsification time, and stability stud-ies. Results: The zeta potential (Y1) and globule size (Y2) of the optimized SEDDS formulation were found to be -36mV and 124.3nm, respectively. The optimized SEDDS formulation showed more than 98% drug release within 15 min in 10% ethanolic 0.1N HCl media, which was significantly higher than that of the pure drug (7.5%) and marketed tablet (~21%). The optimized formulation's self-emulsification time, drug content, and cloud point were 55s, 99.97 ± 1.57 %, and 75.6℃, re-spectively. After stability studies, there was no evidence of phase separation, colour change, and change in globule size. Conclusion:: A significant improvement in in vitro drug release was observed from cilnidipine-loaded-SEDDS.

A large proportion of new chemical moieties are poorly water-soluble. As a result, the biggest challenge for researchers is to enhance the solubility and oral bioavailability of lipophilic drugs. Self-emulsifying systems offer immense potential for improving lipophilic drugs’ oral bioavailability and solubility through various mechanisms such as: inhibiting efflux transporters, absorption of the lipophilic drug through the lymphatic system, and bypassing hepatic first-pass metabolism. These systems dissolve hydrophobic drugs, allowing them to be delivered in a unit dose form for oral administration. Despite much potential, issues like stability, low drug loading, packaging, etc., are associated with the self-emulsifying technique. This review discusses conventional Self-Emulsifying Drug Delivery Systems (SEDDS), which deliver poorly water-soluble drugs. Recent advancements in self-emulsifying systems to solve the issues associated with conventional SEDDS are described exhaustively, including their methodologies and excipients utilized for preparation. The current article also furnishes a literature review on recent advancements in self-emulsifying systems. Recent advances in SEDDS are a great option for overcoming oral bioavailability, stability, and solubility issues of lipophilic drugs. Solid-self emulsifying system can be used to improve the stability of the formulation, hydrophobic ion-pairing for improving mucus permeation properties, while supersaturated self-emulsifying systems with a low concentration of surfactant to overcome issues such as precipitation of drug after dilution and gastrointestinal related side effects. The day will come when medicine companies will see the value of selfemulsifying system developments and adopt this technology for next-generation product releases.

With increasing demand for producing surface composites, Friction Stir Processing [FSP] can be considered as a method that can be imposed in producing surface composites. In Friction Stir Processing [FSP], the basic principle involved is microstructural modification of the specimen to achieve the required properties. This paper aims to provide a brief knowledge about Friction Stir Process [FSP] and to summarize the previous studies carried out with respect to Friction Stir Processing [FSP] and how it facilitates change in local microstructure of the specimen. In this paper, we talk through various factors such as machine parameter and Tool parameters, and many more (Dimensions of the pin and shoulder), which needed to be considered to perform Friction Stir Processing.

Background: Since vedic period, much importance is given for guggulu (Commiphora wightii, (Arn) Bhandari). One can get reference of guggulu as early as 3000 to 10,000 years ago in the veda, for treating human illnesses. References are available regarding usage of guggulu externally as well as internally during the period of charaka, sushruta and vagbhata for the treatment of medoroga and vatavikara. Śhodhana is a preliminary procedure which assist in removing or modifying the possible physical or chemical impurities from raw material and making them suitable for therapeutic use. It has been found clinically that guggulu kalpa usually pass in the faeces un-disintegrated or partially absorbed. To overcome this the kuttana (pounding) method is mentioned to facilitate quick disintegration which in turn helps in quick absorption of guggulu in the body. So present study was taken to know the effect of kuttana on the physico chemical properties of guggulu. Methodology: Guggulu (Commiphora wightii) Shodhana (procedure) was done in Triphala Kwatha and Guggulu (Commiphora wightii) Vati (tablet) were prepared with and without Kuttana (pounding) method. The prepared samples were tested for analytical parameters like organoleptic character, pH, friability, hardness, disintegration time, uniformity of weight, total ash, loss on drying, acid insoluble ash, alcohol soluble extractive, water soluble extractive and HPTLC was done. Result: The organoleptic characters of all the both samples were same. Triphala Shodhita Guggulu (Commiphora wightii) Vati (tablet) prepared with Kuttana (pounding) showed less disintegration time. Pharmaceutical result revealed that the yield was increased in Triphala Shodhita Guggulu (Commiphora wightii). Conclusion: There was a decrease in pH, acid insoluble ash value, water soluble ash value, water soluble extractive value, weight variation value, hardness, disintegration time and increase in Moisture content, Total ash value, Alcohol soluble ash value of Triphala Shodhita Guggulu (Commiphora wightii) Vati (tablet) after Kuttana (pounding). From chromatographical analysis it is observed that a greater number of components were detected.

Objective: Development of pharmaceutical co-crystals is an interesting area of research as co-crystals are unique because they have the advantages of maintaining drug’s intrinsic properties along with improvement in its physicochemical attributes. Objective of this research was to improvise solubility of a Biopharmaceutics Classification System (BCS) class II drug (Ezetimibe) along with better dissolution profile using cocrystallization technique. Methods: In the present study, pharmaceutical cocrystals of a BCS class II drug, Ezetimibe, were prepared using glycine as coformer using neat grinding method. Prepared cocrystals were characterized using Hot Stage Microscopy (HSM), Differential Scanning Calorimetry (DSC), Fourier Transform Infrared (FTIR) and Powder X-Ray Diffract meter (PXRD). In addition, solubility and dissolution studies were also performed. Results: HSM study and DSC study represented melting at Ezetimibe (166 °C), Glycine (233 °C) and cocrystals (174 °C), respectively. Melting point of cocrystal is between API and coformer, indicating towards interaction. During XRD studies, a new peak was observed at 14.7193 and 23.3211 at position 2θ in comparison to parent peaks of Ezetimibe (18.5537, 19.2737 and 21.6487) and Glycine (19.0631, 21.8418, 25.3521, 35.4189, 39.0489 and 39.1631). PXRD pattern of cocrystals represented several newer peaks (-OH group in API shifted from 3241.42 cm-1 to 3202.61 cm-1and-NH2 in Glycine shifted from 1601.86 cm-1 to 1690.18 cm-1). This indicated towards possible interaction between these two-group leading to cocrystal formation. Improvement in dissolution profile of cocrystals (89.59%) was observed over the pure drug (32.41%) in 90 min. Conclusion: Pharmaceutical cocrystals of Ezetimibe with glycine as coformer represented a promising approach in tailoring the physicochemical properties.

Crystallization is a very promising approach to design solid-state properties with desired physicochemical properties. The objective of the present research work was to design, formulate and evaluate Ezetimibe cocrystals. In the present study, Cocrystals of Biopharmaceutics Classification System (BCS) Class II drug, Ezetimibe using 3-pyridine carboxamide as coformer were prepared. 3-pyridine carboxamide was selected as suitable coformer from initial screening. Cocrystals of Ezetimibe with 3-pyridine carboxamide were obtained in 1:1 ratio by solution crystallization method. Hot stage microscopy indicated interaction among drug and coformer. Differential scanning calorimetry spectra of formulated cocrystals reflected shift in endotherm corresponding to melting point in comparison to Ezetimibe, coformer and physical mixture. Fourier transform infrared (FTIR) spectra indicated towards shifting in specific bands characteristic of Ezetimibe. X-Ray Powder Diffraction pattern pointed towards crystallinity and difference in 2θ values of characteristic peaks. The cocrystals showed faster dissolution rate in comparison to Ezetimibe and marketed sample. Pharmacodynamic investigation reveals that cocrystals reduced lipid levels in serum in comparison to pure drug. Pharmaceutical Cocrystals of Ezetimibe with 3-pyridine carboxamide represented a promising approach to improve bioavailability of Ezetimibe drug.

Whether it's God's creation or science, the earth has evolved and life came into existence. Not all have the same character instead exhibit similar. As of reports from the National Institute on Deafness and Communication related disorders 18.5 million(approx.) have speech related disorders. Many are born with speech inability and many get speech-related disorders and are unable to speak. As communication is key for an effective society and environment, a person with speech inability looks different from a normal person. A communication gap exists between a normal person and a person with speech inability. As technological revolutions have taken the world to a new level, still a better and efficient process to make a speech disorder person a normal person is not available. There are many processes and products available but the efficient and reliable ones are not available. The use of Machine Learning and Artificial Intelligence in many fields has high success rates. In this project, a wearable device is to be made with the help of flex sensors and an accelerometer sensor which is to be used by a speech disorder person to communicate with others. There are many sign language systems available, considering the American Sign Language (ASL) system for each alphabet and each numerical dataset is to be created. A comparative study is to be made by applying different machine learning algorithms for the created dataset. The ML algorithm with better performance is identified and to be deployed in microcontroller in the future.

Water softeners helps in removing hardness of water and make them fit for our daily decisive usages. For our work, different water sources like surface water (Hebbal Lake), Bore well water (NPS School, Ozone Urbana, Bangalore) and Corporation water (BWSSB) were selected and their respective hardness as CaCO3 were analysed before and after treatment with Moringa oleifera seed extract. The seeds of Moringa oleifera, one of the best natural coagulants as per the previous studies were used in this protocol. In normal water treatment scheme most preferably ion exchange techniques were used for the removal of hardness, which would likely to be a resin based technology. Also the ion exchange procedure was completely dependent on industrial resins, which were manufactured by major corporate concerns (like Lancer, Toyota, Ion Exchange India Ltd, Thermax Ltd, LG etc.), hence incur huge cost. Industrial resins have Na+ ions attached to the resin beads replaces Ca2+ and Mg2+ ions present in water during the ion exchange process. The resin beads can be regenerated or recharged again with Na+ ion by NaCl solution once the resin gets exhausted. Our work persuaded in another way of removing hardness from water by the principle means of adsorption and conversion of soluble hardness-causing ions to insoluble products by precipitation reactions. Moringa oleifera seed extracts were prepared and performed jar test to obtain the best required dosage for hardness removal in the selected water samples. The obtained dosage (mg/l) or ppm of Moringa oleifera was dosed to the selected water samples through the dosing system present in an existing water treatment system of capacity 2 m3/hr. The removal efficiency was observed to be between 50 to 60% after passing through the treatment system with Moringa oleifera dosage. Hence this work can pave way to find a best alternate method for hardness removal water.